Mark Jon Olsen

Title: Mark Jon Olsen: Innovator in Pharmaceutical Compounds

Introduction

Mark Jon Olsen is a distinguished inventor based in Phoenix, AZ, known for his significant contributions to the field of pharmaceutical compounds. With a total of nine patents to his name, Olsen has made remarkable strides in developing innovative solutions for various medical applications.

Latest Patents

Olsen's latest patents include isotopically-stabilized tetronimide compounds, which comprise one or more deuterium atoms, along with their derivatives and intermediates. These compounds are designed for synthesis and pharmaceutical compositions, aimed at interacting with target molecules in various assays and models. One notable aspect of this invention involves molecules that modulate the expression or catalytic activity of aspartyl (asparaginyl) β-hydroxylase (ASPH) within or on the surface of a cell. Additionally, these compounds have potential applications in diagnosing, ameliorating, or treating cell proliferation disorders and related diseases. Another significant patent involves monoclonal antibodies targeting specific epitopes of ASPH, which can be utilized in therapeutic and diagnostic applications.

Career Highlights

Throughout his career, Mark Jon Olsen has worked with reputable institutions such as Midwestern University and Rhode Island Hospital. His work has focused on advancing the understanding and treatment of various medical conditions through innovative pharmaceutical solutions.

Collaborations

Olsen has collaborated with notable colleagues, including John-Michael Thomas and Jack Raymond Wands, contributing to the development of groundbreaking medical technologies.

Conclusion

Mark Jon Olsen's innovative work in pharmaceutical compounds has the potential to significantly impact the medical field. His contributions through patents and collaborations highlight his dedication to advancing healthcare solutions.